Supernus Pharmaceuticals, Inc. (SUPN) - Financial and Strategic SWOT Analysis Review

Date: June 28, 2016
Pages: 56
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S02A37BDA45EN
Leaflet:

Download PDF Leaflet

Supernus Pharmaceuticals, Inc. (SUPN) - Financial and Strategic SWOT Analysis Review
Supernus Pharmaceuticals, Inc. (SUPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR, an adjunct therapy for the treatment of partial seizures; and Trokendi XR, an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals, Inc. Key Recent Developments

May 03, 2016: Supernus Announces First Quarter 2016 Financial Results
Apr 01, 2016: Supernus Pharmaceuticals Selects DSG for EDC and IWRS in Phase 3 Clinical Studies on Impulsive Aggression in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder
Mar 02, 2016: Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results
Nov 03, 2015: Supernus Announces Third Quarter 2015 Financial Results and Raises 2015 Guidance
Aug 04, 2015: Supernus Announces Second Quarter 2015 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Supernus Pharmaceuticals, Inc. - Key Facts
Supernus Pharmaceuticals, Inc. - Key Employees
Supernus Pharmaceuticals, Inc. - Key Employee Biographies
Supernus Pharmaceuticals, Inc. - Major Products and Services
Supernus Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
Supernus Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Supernus Pharmaceuticals, Inc., Pipeline Products by Development Phase
Supernus Pharmaceuticals, Inc. - History
Supernus Pharmaceuticals, Inc. - Company Statement
Supernus Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Supernus Pharmaceuticals, Inc. - Business Description
Supernus Pharmaceuticals, Inc. - Corporate Strategy
Supernus Pharmaceuticals, Inc. - SWOT Analysis
SWOT Analysis - Overview
Supernus Pharmaceuticals, Inc. - Strengths
Strength - Epilepsy Portfolio
Strength - Propreitary Technologies
Strength - Research and Development
Supernus Pharmaceuticals, Inc. - Weaknesses
Weakness - Competitive Positioning
Weakness - Cost Control
Weakness - Patent Infringement Lawsuit
Supernus Pharmaceuticals, Inc. - Opportunities
Opportunity - Product Pipeline
Opportunity - Market Potential – Epilepsy
Opportunity - Fast Track Designation
Supernus Pharmaceuticals, Inc. - Threats
Threat - Competitive Pressures
Threat - Stringent Government Regulations
Threat - Reliance on Contract Manufacturers
Supernus Pharmaceuticals, Inc. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Supernus Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Supernus Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Supernus Pharmaceuticals, Inc., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 03, 2016: Supernus Announces First Quarter 2016 Financial Results
Apr 01, 2016: Supernus Pharmaceuticals Selects DSG for EDC and IWRS in Phase 3 Clinical Studies on Impulsive Aggression in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder
Mar 02, 2016: Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results
Nov 03, 2015: Supernus Announces Third Quarter 2015 Financial Results and Raises 2015 Guidance
Aug 04, 2015: Supernus Announces Second Quarter 2015 Financial Results
May 05, 2015: Supernus Announces First Quarter 2015 Financial Results
Mar 23, 2015: Georges Gemayel, Ph.D., Joins Supernus Board of Directors
Mar 10, 2015: Supernus Announces Fourth Quarter and Full Year 2014 Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Supernus Pharmaceuticals, Inc., Key Facts
Supernus Pharmaceuticals, Inc., Key Employees
Supernus Pharmaceuticals, Inc., Key Employee Biographies
Supernus Pharmaceuticals, Inc., Major Products and Services
Supernus Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
Supernus Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
Supernus Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
Supernus Pharmaceuticals, Inc., History
Supernus Pharmaceuticals, Inc., Subsidiaries
Supernus Pharmaceuticals, Inc., Key Competitors
Supernus Pharmaceuticals, Inc., Ratios based on current share price
Supernus Pharmaceuticals, Inc., Annual Ratios
Supernus Pharmaceuticals, Inc., Interim Ratios
Supernus Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Supernus Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Supernus Pharmaceuticals, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Supernus Pharmaceuticals, Inc., Pipeline Products by Therapy Area
Supernus Pharmaceuticals, Inc., Pipeline Products by Development Phase
Supernus Pharmaceuticals, Inc., Performance Chart (2011 - 2015)
Supernus Pharmaceuticals, Inc., Ratio Charts
Supernus Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Supernus Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Upsher-Smith Laboratories, Inc.
Shire Plc
Otsuka America, Inc.
Novartis Corporation
Alcobra Ltd
Skip to top


Ask Your Question

Supernus Pharmaceuticals, Inc. (SUPN) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: